Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.
Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.
In one line: A small Chinese GE Healthcare contrast-agent unit.
Moat: narrow (regulatory licence, distribution). Licensed isotope handling and a national contrast-agent distribution network are hard to replicate.
Headquarters: Yantai, China · Employees: 2,583
Size Yantai Dongcheng Biochemicals (002675.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 1439th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.53 on 18 Nov 2026.
Performance Over six months the shares fell 0.2%, against -11.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 4.2% over the last twelve months (peer median +6.6%); the operating margin is 14.8% (peer median 9.9%).
Valuation It trades at 47.2× forward earnings against a peer median of 25.6× (4th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.63B | CN¥2.72B | CN¥2.85B | CN¥3.26B | CN¥3.57B |
| Revenue growth | — | -5% | -12% | -9% | — |
| Gross profit | CN¥1.50B | CN¥1.30B | CN¥1.26B | CN¥1.40B | CN¥1.48B |
| EBITDA | n/a | CN¥572M | CN¥456M | CN¥529M | CN¥680M |
| Net income | CN¥210M | CN¥196M | CN¥184M | CN¥210M | CN¥307M |
| Free cash flow | CN¥112M | CN¥224M | -CN¥163M | -CN¥203M | CN¥615M |
| Capital expenditure | CN¥388M | CN¥361M | CN¥456M | CN¥512M | CN¥390M |
| Total debt | CN¥1.49B | CN¥2.61B | CN¥2.26B | CN¥1.72B | CN¥1.84B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yantai Dongcheng Biochemicals 002675.SZ | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002675.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | -5.8% | 8th highest of 21 |
| 6-month return | -0.2% | -11.9% | 6th highest of 20 |
| Distance from 52-week high | -22.4% | -36.7% | 8th highest of 21 |
| Revenue growth (TTM) | -4.2% | +6.6% | 9th lowest of 20 |
| Operating margin | 14.8% | 9.9% | 8th highest of 20 |
| Forward P/E | 47.2× | 25.6× | 4th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 6.0% | 12.1% | 7th least demanding of 15 |
| Growth delivered (Del g) | -4.3% | +4.3% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +10.3 pp | +4.8 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +1.4 pp | -1.0 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |